AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03102840 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: blood sampling
Description: Blood sampling will be done by finger-prick in a sub-set of participants
Study NCT01422967 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Balance and muscle strength
Description: Balance test: bi and unipodal balance in the place force Muscle strength: bilateral test of knee in dynamometer isokinetic
Study NCT01397825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib (MLN8237)
Description: Alisertib (MLN8237) enteric coated tablet (ECT).
Study NCT01397825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab IV infusion.
Study NCT01397825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine IV Infusion.
Study NCT03368859 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil - bolus
Description: Intravenous
Study NCT03483194 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Kalinox
Description: Usually take care of by a gas mixture composed of 50% Nitrous Oxide, 50% Oxygen for the medical procedure (osteo-medullary biopsy)
Study NCT03650985 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fetoscope technique
Description: Intrauterine intervention with fetoscope technique will be applied to treat complex twin diseases with intention to improve the prognosis of patients.
Study NCT01421264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: 300mg capsules by mouth
Study NCT03082872 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cemented K-wire
Description: Fracture of proximal phalanx was treated with Cemented K-wire.
Study NCT03082872 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transfixion Pinning
Description: Fracture of proximal phalanx was treated with transfixion pinning.
Study NCT03368859 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Intravenous
Study NCT02400359 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lorcaserin HCl
Description: Lorcaserin is a weight-loss drug developed by Arena Pharmaceuticals. It has serotonergic properties and acts as an anorectic.
Study NCT02400359 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This is a placebo oral pill that is a visual replica of the Lorcaserin medication but with no active ingredients.
Study NCT01666899 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin and blood vessel procedures
Description: Biopsies, skin blood flow studies and ultrasound studies will be performed as described.
Study NCT02758496 — intervention group
Intervention type: OTHER
Intervention: MeRT Efficacy Chart Review
Description: There will be not intervention. This is a chart review.
Study NCT03079466 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: This is a randomized study where patients are included consecutively under a randomization order that will be given to the investigators. Patients will continue to be treated with CPAP and other treatment with no CPAP for a duration of 3 months and with intention-to-treat analysis And by protocol.
Study NCT04086979 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parental Friendship Coaching
Description: In this condition, therapists instructed parents in ways to coach their children to display better friendship behaviors using skills teaching, role play, active practice, and homework. This is a 10 week group intervention.
Study NCT03079466 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: CPAP
Description: This is a randomized study where patients are included consecutively under a randomization order that will be given to the investigators. Patients will continue to be treated with CPAP and other treatment with no CPAP for a duration of 3 months and with intention-to-treat analysis And by protocol.
Study NCT03974035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Second infiltration pre-extubation with ropivacaine
Description: The surgeon will proceed firstly with pre-incisional infiltration with lidocaine and adrenaline after intubation, and secondly with pre-extubation infiltration with ropivacaine at the intraoral and intranasal submucosal level in the maxilla and jaw to block the terminal branches of the maxillary and mandibular nerve
Study NCT01209793 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: REGN846
Description: 5 IV cohorts (Dose 1, 2, 3, 4, 5)
Study NCT03492372 — intervention group
Intervention type: OTHER
Intervention: Waste tissues are collected at the time of spinal surgery.
Description: This is a single visit study. Waste tissues are collected at the time of spinal surgery.
Study NCT03502395 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: ): Patients were received intravenous 1 mg/kg of 2 % lidocaine as a loading dose (just before induction of anesthesia) then received 2mg/kg /h lidocaine as maintenance dose (with maximum of 200 mg/h) till the end of the operation (skin closure).
Study NCT03502395 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: A standardized equal volume of intravenous bolus dose of normal saline was given as loading dose then normal saline was administered on an equal rate of infusion.
Study NCT00582673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AFQ056
Study NCT00582673 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03224494 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Rapid Barostat Bag
Description: Both healthy controls (n= 100) and IBS patients (n=100) will undergo anorectal studies using a Rapid barostat bag catheter.
Study NCT03224494 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: IBS severity scoring system questionnaire (IBS-SSS)
Description: We will correlate the changes to IBS symptoms using the IBS severity scoring system questionnaire (IBS-SSS). The questionnaire will be administered twice for IBS patients who have consented to return for a second study visit, at each of the two RBB studies.
Study NCT03224494 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: HAD scale questionnaire
Description: It is a validated anxiety and depression questionnaire
Study NCT03657953 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: surgical approach
Study NCT04086979 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Coping with ADHD through Relationships and Education
Description: In this condition, the therapist provided parents with psychoeducation about ADHD and friendship difficulties, and encouraged them to apply this information to their child and to support one another with tips about how to address these problems. This is a 10 week group intervention.
Study NCT01354054 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High Frequency TENS
Description: 100 usec, 100 Hz, pulse amplitude motor - 10%, 30-40 minutes
Study NCT01354054 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low frequency TENS
Description: 100 usec, 4 Hz, pulse amplitude motor - 10%, 30-40 minutes
Study NCT03093519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK6640
Description: Intravenous administration
Study NCT03093519 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous administration
Study NCT00262288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: i.v. recombinant human C1 inhibitor
Study NCT02953093 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Acarbose
Description: see arm description
Study NCT03368859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil - infusion
Description: Intravenous
Study NCT01354054 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Placebo TENS
Description: 100 usec, 100 Hz, motor - 10%, pulse amplitude adjusted and maintained for 30 seconds then ramping down to zero in 15 seconds
Study NCT02925533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B-701
Description: B-701 is a phage-derived, affinity-matured, human monoclonal antibody (mAb) specific for FGFR3. It is based on a human immunoglobulin G1 (IgG1) framework containing heavy chain VHIII and light chain VκI subgroup sequences.
Study NCT02925533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is an mAb that binds to the programmed cell death protein 1 (PD-1) receptor and blocks its interaction with programmed death-ligand 1 (PD-L1) and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. In syngeneic mouse tumor models, blocking PD-1 activity resulted in decreased tumor growth.
Study NCT01877733 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maximal strength training
Study NCT02895997 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Travel Telehealth Delivery
Description: Clinical Operations Room (COR) staff will travel to Sydney Australia to deliver telehealth to patients in Georgia United States. Upon arrival, participants will have eight nights and seven days free of clinical responsibilities. Thereafter, each participant will work four consecutive days of 12 hour shifts followed by four consecutive days with no clinical assignment. The following week, participants will work three consecutive days of 12 hour shifts followed by four consecutive days with no clinical assignment. Upon return to the USA, participants will have a week free of clinical responsibilities.
Study NCT01020006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCI-27483
Description: Part A: Closed to enrollment.Part B: Approximately 20 patients will be randomized to the control arm that will receive a standard regimen of gemcitabine and 20 patients will be randomized to the PCI-27483 arm and treated with both gemcitabine and PCI-27483. PCI-27483 will be administered as subcutaneous (SC) injections, nominally at a dosage of 1.2 mg/kg BID. Patients receiving PCI-27483 with a tumor response or stable disease at 12 weeks will have the option to continue PCI-27483 treatment until disease progression or the investigator considers the study treatment no longer tolerable. Treatment with gemcitabine may continue per standard of care.~All evaluable patients will roll over into Part C at week 16 (Day 113±5). If 2 consecutive INRs at 2 hours postdose are >3.50,a reduced dosage will be calculated.
Study NCT01020006 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Study NCT01020006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Study NCT01661088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX
Description: Starting dose levels as following:~Oxaliplatin 85mg/m2 intravenously over 120 minutes on day 1. Irinotecan 180mg/m2 intravenously over 90 minutes on day 1. NOTE: patients homozygous for the UGT1A1 (TA)7 promoter allele will be treated at an initial lower dose 140mg/m2 (please see Section 6.3.a) Leucovorin 400mg/m2 intravenously over 90 minutes on day 1. 5FU 400mg/m2 as bolus intravenous injection following leucovorin on day 1. 5FU 2,400mg/m2 infused intravenously as a continuous infusion over 46 hours following the bolus 5FU, beginning on day 1.
Study NCT01661088 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy (IMRT)
Description: 50.0Gy in 2.0Gy per fraction
Study NCT01661088 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Exploration
Description: Patients without metastatic disease will be offered surgical exploration.
Study NCT03368859 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil - infusion
Description: Intravenous
Study NCT03368859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-165
Description: Intravenous
Study NCT03368859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Intravenous
Study NCT03368859 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Intravenous
Study NCT02698410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanreotide (Autogel formulation) and Temozolomide
Study NCT01901224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin 1000 mg
Study NCT01901224 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03802721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-benzo[a]pyrene
Description: Oral micro-dose (50 ng) (5.4 nCi)
Study NCT03802721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brussels sprouts before 50 ng dose
Description: Brussels sprouts for 7 days before 50 ng (5.4 nCi) dose of BaP
Study NCT03802721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DIM supplement before 50 ng dose
Description: DIM supplement for 7 days before 50 ng (5.4 nCi) dose of BaP and coadministration with DIM supplement
Study NCT01817257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Molecular Weight Heparin (LMWH)
Description: Participants randomised to Arm A will have already received LMWH (Fragmin®), tinzaparin (Innohep®) or enoxaparin (Clexane®) at treatment dose for six months off trial, and should continue the same drug at the same dose for a further six months on trial. No dose alterations are required unless clinically indicated.
Study NCT01662089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 15 mg Chelate zinc supplement
Description: 15 mg Chelate zinc additional to standard 5% minoxidil
Study NCT01662089 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drug supplement
Description: Placebo drug instead of Zinc supplement
Study NCT02300129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD07805/47, CD07805/47+Placebo, Placebo, CD07805/47, Placebo
Description: Period 1:~1g of CD07805/47 0.5% Gel on full face on Day 1 and 500mg on a half-face on Day 3.~500mg of Placebo Gel on a half-face on Day 3 and 1g on full face on Day 5.~Period 2:~1g of CD07805/47 0.5% Gel on full face once daily 7 days per week for 2 weeks.~1g of Placebo Gel on full face once daily 7 days per week the 2 following weeks.
Study NCT02300129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo, CD07805/47+Placebo, CD07805/47, CD07805/47, Placebo
Description: Period 1:~1g of Placebo Gel on full face on Day 1 and 500mg on a half-face on Day 3.~500mg of CD07805/47 0.5% Gel on a half-face on Day 3 and 1g on full face on Day 5.~Period 2:~1g of CD07805/47 0.5% Gel on full face once daily 7 days per week for 2 weeks.~1g of Placebo Gel on full face once daily 7 days per week the 2 following weeks.
Study NCT02300129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD07805/47, CD07805/47+Placebo, Placebo, Placebo, CD07805/47
Description: Period 1:~1g of CD07805/47 0.5% Gel on full face on Day 1 and 500mg on a half-face on Day 3.~500mg of Placebo Gel on a half-face on Day 3 and 1g on full face on Day 5.~Period 2:~1g of Placebo on full face once daily 7 days per week for 2 weeks.~1g of CD07805/47 0.5% Gel on full face once daily 7 days per week the 2 following weeks.
Study NCT02300129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo, CD07805/47+Placebo, CD07805/47, Placebo, CD07805/47
Description: Period 1:~1g of Placebo Gel on full face on Day 1 and 500mg on a half-face on Day 3.~500mg of CD07805/47 0.5% Gel on a half-face on Day 3 and 1g on full face on Day 5.~Period 2:~1g of Placebo on full face once daily 7 days per week for 2 weeks.~1g of CD07805/47 0.5% Gel on full face once daily 7 days per week the 2 following weeks.
Study NCT05048290 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Communication Skills Training
Description: Participate in communication workshops
Study NCT05048290 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Communication Skills Training
Description: Participate in generic communication skills workshops
Study NCT05048290 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Develop a video
Study NCT05048290 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Complete surveys
Study NCT05048290 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Complete surveys
Study NCT00740805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT00740805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study NCT00740805 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00740805 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT00740805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Given PO
Study NCT03530449 — intervention group
Intervention type: DEVICE
Intervention: OCT Angiography
Description: OCT Angiography offers clinicians a non-invasive three-dimensional visualization of vasculature in the retina and choroid. The visualization of perfused vasculature in a three-dimensional layout, offers clinicians an aid in the identification of retinal and choroidal pathologies such as retinal ischemia, microaneurysms, retinal neovascularization and choroidal neovascular membranes.
Study NCT03530449 — intervention group
Intervention type: DEVICE
Intervention: Color Fundus Photography
Description: Non-contact white light photography
Study NCT03530449 — intervention group
Intervention type: DEVICE
Intervention: Optical Coherence Tomography
Description: Two and Three dimensional cross sectional imaging of the back of the eye to look at vascular structures and is an aid in the detection and management of various ocular diseases.
Study NCT01198158 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study NCT01198158 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: Given PO
Study NCT01198158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Given PO
Study NCT01198158 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01198158 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03744650 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care4Heart programme
Description: A 4-week mHealth programme in the form of a smartphone app, named Care4Heart, has been developed. The content and scope of the design are developed by a thorough literature review and an extensive analysis of existing education leaflets and brochures used to prevent CHD. The contents are specified and tailored to the working population.~The app is developed by a team of software engineers from Computing School of NUS. Several functions include: (1) app using instructional video; (2) easy-to-read information on healthy lifestyle toward heart health, including information about the disease, CHD risk factors (e.g. diet, smoking cessation), stress, physical exercises and relaxation techniques; and (3) scheduled reminders for doing exercise and relaxation
Study NCT02083276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pivmecillinamhydrochlorid
Description: PO 400 mg x3 for 7 days
Study NCT04079023 — intervention group
Intervention type: PROCEDURE
Intervention: Sleeve Gastrectomy
Description: Subtotal vertical gastrectomy
Study NCT02861170 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Mindfulness-Based Intervention
Description: In addition to the educational materials that will be provided to all participants, the participants in the intervention group will also receive a 10-minute mindfulness-based intervention called a body scan. The body scan is a guided meditation exercise where participants are lead through focusing their attention on their body while maintaining awareness and acceptance of their sensations, emotions, and thoughts without trying to control or change them. The goal of the intervention is to increase mindfulness (i.e., moment-to-moment, non-judgmental and non-reactive awareness of sensations, emotions and thoughts), to provide self-regulation strategies, and to promote healthy and adaptive responses to stress.
Study NCT02521129 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biopsy Track Ablator (STARmed, Goyang, Korea)
Description: After percutaneous ultrasound guided biopsy for hepatic masses is performed, biopsy track is ablated with a new track ablation device.
Study NCT03361501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CaPre
Description: 4 x 1 g capsules administered orally once daily for 26 weeks
Study NCT03361501 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 x 1 g capsules administered orally once daily for 26 weeks
Study NCT01217606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bimatoprost/brimonidine tartrate/timolol ophthalmic solution (Triple Combination Therapy)
Description: One drop of Triple Combination Therapy administered to each eye, twice daily for up to 12 months.
Study NCT01217606 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution
Description: One drop of Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution administered to each eye, twice daily for up to 12 months.